CS1（信号淋巴细胞激活分子家族成员7，CD319）是多发性骨髓瘤的有效免疫治疗靶点。
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
作者信息
Malaer Joseph D, Mathew Porunelloor A
机构信息
Institute for Molecular Medicine, University of North Texas Health Science Center3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA.
出版信息
Am J Cancer Res. 2017 Aug 1;7(8):1637-1641. eCollection 2017.
Abstract
CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.
摘要
CS1（也称为CD319、CRACC和SLAMF7）被鉴定为一种调节免疫功能的自然杀伤（NK）细胞受体。它也在B细胞、T细胞、树突状细胞、NK-T细胞和单核细胞上表达。CS1在多发性骨髓瘤中过度表达，使其成为免疫治疗的靶点。一种人源化抗CS1抗体埃罗妥珠单抗（Elotuzumab）或Empliciti在临床研究中已显示出有前景的结果。本综述聚焦于CS1在NK细胞和其他造血细胞以及多发性骨髓瘤中的生物学特性。抗CS1单克隆抗体可激活NK细胞的自然细胞毒性以及增强抗体依赖性细胞介导的细胞毒性（ADCC），因此成为多发性骨髓瘤免疫治疗的有效靶点。
相似文献
1
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Am J Cancer Res. 2017 Aug 1;7(8):1637-1641. eCollection 2017.
2
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Oncoimmunology. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853. eCollection 2017.
3
2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer.
Clin Immunol. 2019 Jul;204:50-56. doi: 10.1016/j.clim.2018.10.009. Epub 2018 Oct 19.
4
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.
5
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Crit Rev Oncol Hematol. 2013 Oct;88(1):168-77. doi: 10.1016/j.critrevonc.2013.04.003. Epub 2013 Jun 2.
6
Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Blood Lymphat Cancer. 2014 Jun;2014(4):15-27. doi: 10.2147/BLCTT.S49780.
7
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Cancer Immunol Immunother. 2022 Oct;71(10):2497-2509. doi: 10.1007/s00262-022-03177-6. Epub 2022 Mar 9.
8
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Front Immunol. 2018 Nov 5;9:2551. doi: 10.3389/fimmu.2018.02551. eCollection 2018.
9
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1.
10
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Ther Adv Hematol. 2016 Oct;7(5):288-301. doi: 10.1177/2040620716657993. Epub 2016 Jul 15.
引用本文的文献
1
Recent advances in tumor immunotherapy based on NK cells.
Front Immunol. 2025 Aug 7;16:1595533. doi: 10.3389/fimmu.2025.1595533. eCollection 2025.
2
Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma.
Front Immunol. 2025 Jul 31;16:1613222. doi: 10.3389/fimmu.2025.1613222. eCollection 2025.
3
SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism.
Gut Microbes. 2025 Dec;17(1):2527857. doi: 10.1080/19490976.2025.2527857. Epub 2025 Jul 11.
4
Altered Expression of NK Receptors in Racially/Ethnically Diverse and Risk-of-Relapse Pediatric Acute Lymphoblastic Leukemia Patients.
Biomedicines. 2025 Jun 9;13(6):1412. doi: 10.3390/biomedicines13061412.
5
Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.
Cancers (Basel). 2025 Apr 7;17(7):1247. doi: 10.3390/cancers17071247.
6
Gene Expression Signatures of Smoking and Acute Myocardial Infarction: A Blood Transcriptome Analysis.
Mediators Inflamm. 2025 Jan 15;2025:2431090. doi: 10.1155/mi/2431090. eCollection 2025.
7
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.
Exp Hematol Oncol. 2024 Oct 28;13(1):105. doi: 10.1186/s40164-024-00576-6.
8
Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma.
Front Immunol. 2024 Sep 25;15:1469794. doi: 10.3389/fimmu.2024.1469794. eCollection 2024.
9
Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.
Front Immunol. 2024 Jul 30;15:1422478. doi: 10.3389/fimmu.2024.1422478. eCollection 2024.
10
Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.
Arch Dermatol Res. 2024 Jul 18;316(7):478. doi: 10.1007/s00403-024-03182-y.
本文引用的文献
1
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Br J Haematol. 2017 Sep;178(6):896-905. doi: 10.1111/bjh.14787. Epub 2017 Jul 5.
2
Immunologic approaches for the treatment of multiple myeloma.
Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6.
3
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Nature. 2017 Apr 27;544(7651):493-497. doi: 10.1038/nature22076. Epub 2017 Apr 19.
4
Natural killer cell memory in infection, inflammation and cancer.
Nat Rev Immunol. 2016 Feb;16(2):112-23. doi: 10.1038/nri.2015.9. Epub 2016 Jan 25.
5
Cancer statistics, 2016.
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
6
Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
Immunobiology. 2016 Jan;221(1):31-9. doi: 10.1016/j.imbio.2015.08.005. Epub 2015 Aug 15.
7
Natural Killer Cell Immunotherapy: From Bench to Bedside.
Front Immunol. 2015 Jun 3;6:264. doi: 10.3389/fimmu.2015.00264. eCollection 2015.
8
NK cells and interferons.
Cytokine Growth Factor Rev. 2015 Apr;26(2):113-20. doi: 10.1016/j.cytogfr.2014.11.003. Epub 2014 Nov 13.
9
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.
10
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
Zotero 插件